Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Frilabiol Sleep (also marketed as Frilabiol Sommeil) is an oral sleep aid developed by the Swiss pharmaceutical laboratory FRiLAB. Classified as a food supplement rather than a traditional pharmaceutical drug, it utilizes a phytotherapy-based "triple therapy" approach to manage difficult sleep in adults and children over 12 years of age. The product is administered as a capsule once daily, approximately 30 to 45 minutes before bedtime. As a phytotherapeutic product, it is designed to promote relaxation and improve sleep quality through plant-derived active ingredients, although specific chemical constituents and biological targets are not disclosed in standard pharmaceutical pipeline documentation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Frilabiol Sleep.